Study: Teledermatology Can Improve Access to Medical Specialists

May 5, 2016
Offering virtual dermatology care to Medicaid recipients can be one potential way to increase access to medical specialists who are in short supply, according to a new RAND Corporation study.

Offering virtual dermatology care to Medicaid recipients can be one potential way to increase access to medical specialists who are in short supply, according to a new RAND Corporation study.

Researchers found that after the introduction of a teledermatology service, the number of patients who received care from a dermatologist nearly doubled, with greater utilization of dermatology care among patients treated in primary care practices that began using the service, as compared to patients seen by primary care practices that did not use the teledermatology service.

The study, published in the May edition of the journal JAMA Dermatology, found that teledermatology generally served younger and healthier patients who had more-targeted and potentially less-severe skin conditions, such as acne and warts. Researchers analyzed the experiences of more than 380,000 Medicaid enrollees in California's central valley, including about 108,000 who were newly enrolled under provisions of the Affordable Care Act. The region has only about one-third as many dermatologists per 100,000 residents as the national average.

The Health Plan of San Joaquin, a MediCal managed plan, for instance, began offering teledermatology to its members in April 2012, although not all of the primary care practices in the system began referring patients to the service. (Medicaid is called MediCal in California.) The teledermatology model implemented in this health plan involved both consultative and direct-care elements. Some primary care physicians who referred patients to teledermatology provided background about patients and took digital images of skin problems, which were uploaded to a secure website. They then received a consult report within a few days.

However, over time most primary care practices that referred patients to teledermatology used a more direct-care model. Patients with skin problems were referred by their physician to two brick-and-mortar clinics to have photographs taken and to be interviewed by a teledermatology nurse. The remote dermatologist then reviewed the history and images, with the diagnosis and treatment relayed to both the patient and referring primary care provider. If necessary, an in-person follow-up visit was scheduled at the clinic, where a teledermatologist was regularly onsite. As such, the study found that patients in primary care practices that were referred to teledermatology were more likely to have one or more visits with a dermatologist and the rate of visits with dermatologists also increased.

After it was introduced, teledermatology served half of all enrollees who received any dermatology care. Among those newly enrolled under the Affordable Care Act, teledermatology served three-quarters of patients with any dermatology care in 2014. People who had more-complex problems such as psoriasis and skin cancers were more likely to visit a dermatologist in-person than other patients.

"While in-person dermatologists served many of the patients with the greatest medical need, teledermatology expanded access to a new group of enrollees with different demographics and different needs," Lori Uscher-Pines, the study's lead author and a policy researcher at RAND, said in a statement. "Our findings show that among at least one large population of Medicaid patients, teledermatology can improve access to medical specialists."

Sponsored Recommendations

Ask the Expert: Is Your Patients' Understanding Putting You at Risk?

Effective health literacy in healthcare is essential for ensuring informed consent, reducing medical malpractice risks, and enhancing patient-provider communication. Unfortunately...

Beyond the Silos: Transforming Coordinated Care Across Healthcare Systems

Coordinated healthcare is vital to delivering a high-quality patient experience, yet it has been difficult to systematize across all healthcare settings. Although it has largely...

The Healthcare Provider's Guide to Accelerating Clinician Onboarding

Improve clinician satisfaction and productivity to enhance patient care

ASK THE EXPERT: ServiceNow’s Erin Smithouser on what C-suite healthcare executives need to know about artificial intelligence

Generative artificial intelligence, also known as GenAI, learns from vast amounts of existing data and large language models to help healthcare organizations improve hospital ...

According to an Oct. 10 press release, a report by the World Health Organization (WHO) finds that vaccines against 24 pathogens could reduce the number of antibiotics needed by 22% or 2.5 billion defined daily doses globally every year, supporting worldwide efforts to address antimicrobial resistance (AMR). While some of these vaccines are already available but underused, others would need to be developed and brought to the market as soon as possible. AMR occurs when bacteria, viruses, fungi, and parasites no longer respond to antimicrobial medicines, making people sicker and increasing the risk of illness, death and the spread of infections that are difficult to treat. AMR is driven largely by the misuse and overuse of antimicrobials, yet, at the same time, many people around the world do not have access to essential antimicrobials. Each year, nearly 5 million deaths are associated with AMR globally. Vaccines are an essential part of the response to reduce AMR as they prevent infections, reduce the use and overuse of antimicrobials, and slow the emergence and spread of drug-resistant pathogens. The new report expands on a WHO study published in BMJ Global Health last year. It estimates that vaccines already in use against pneumococcus pneumonia, Haemophilus influenzae type B (Hib, a bacteria causing pneumonia and meningitis) and typhoid could avert up to 106 000 of the deaths associated with AMR each year. An additional 543 000 deaths associated with AMR could be averted annually when new vaccines for tuberculosis (TB) and Klebsiella pneumoniae, are developed and rolled out globally. While new TB vaccines are in clinical trials, one against Klebsiella pneumoniae is in early stage of development.
dreamstime_xxl_210174616_1